Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases

Research output: Contribution to journalJournal articleResearchpeer-review

  1. High-pressure NIV for acute hypercapnic respiratory failure in COPD: improved survival in a retrospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Ensuring basic competency in chest tube insertion using a simulated scenario: an international validation study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exploration of the induced cytokine responses in European Lyme neuroborreliosis: A longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Endotheliopathy is associated with slower liberation from mechanical ventilation: a cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Responses to COVID-19 vaccination in patients with chronic pulmonary diseases are poorly characterised. We aimed to describe humoral responses following two doses of BNT162b2 mRNA COVID-19 vaccine and identify risk factors for impaired responses.

METHODS: Prospective cohort study including adults with chronic pulmonary diseases and healthcare personnel as controls (1:1). Blood was sampled at inclusion, 3 weeks, 2 and 6 months after first vaccination. We reported antibody concentrations as geometric means with 95% CI of receptor binding domain (RBD)-IgG and neutralising antibody index of inhibition of ACE-2/RBD interaction (%). A low responder was defined as neutralising index in the lowest quartile (primary outcome) or RBD-IgG <225 AU/mL plus neutralising index <25% (secondary outcome), measured at 2 months. We tested associations using Poisson regression.

RESULTS: We included 593 patients and 593 controls, 75% of all had neutralising index ≥97% at 2 months. For the primary outcome, 34.7% of patients (n=157/453) and 12.9% of controls (n=46/359) were low responders (p<0.0001). For the secondary outcome, 8.6% of patients (n=39/453) and 1.4% of controls (n=5/359) were low responders (p<0.001). Risk factors associated with low responder included increasing age (per decade, adjusted risk ratio (aRR) 1.17, 95% CI 1.03 to 1.32), Charlson Comorbidity Index (per point) (aRR 1.15, 95% CI 1.05 to 1.26), use of prednisolone (aRR 2.08, 95% CI 1.55 to 2.77) and other immunosuppressives (aRR 2.21, 95% CI 1.65 to 2.97).

DISCUSSION: Patients with chronic pulmonary diseases established functional humoral responses to vaccination, however lower than controls. Age, comorbidities and immunosuppression were associated with poor immunological responses.

Original languageEnglish
Article numbere001268
JournalBMJ Open Respiratory Research
Volume9
Issue number1
ISSN2052-4439
DOIs
Publication statusPublished - Jul 2022

Bibliographical note

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

    Research areas

  • asthma, bronchiectasis, copd epidemiology, COVID-19, interstitial fibrosis

ID: 79189695